---
title: "Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286273988.md"
description: "Craig-Hallum analyst Adam Vogel has reaffirmed a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $36.00. Vogel, a 4-star analyst with a 32.2% average return and 94.12% success rate, focuses on the Healthcare sector. Additionally, Piper Sandler also maintains a Buy rating on LBRX, setting a higher price target of $78.00."
datetime: "2026-05-13T13:45:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286273988.md)
  - [en](https://longbridge.com/en/news/286273988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286273988.md)
---

# Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

Craig-Hallum analyst Adam Vogel maintained a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $36.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Vogel is a 4-star analyst with an average return of 32.2% and a 94.12% success rate. Vogel covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, LB Pharmaceuticals, Inc., and Immunome.

In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $78.00 price target.

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [IMNM.US](https://longbridge.com/en/quote/IMNM.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286260357.md)
- [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md)